Trial reportTrials2026
Incremental value of non-pharmacokinetic adherence measures for dapivirine vaginal ring use in resource limited setting.
Trial report in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01539226 (A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Safety and Efficacy Trial of a Dapivirine Vaginal Matrix Ring in Healthy HIV-Negative Women
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeasuring product use adherence remains a challenge in HIV prevention trials and routine care setting. We determined agreement among and between non-pharmacokinetic (non-PK) and pharmacokinetic (PK) adherence measures, and also assessed the incremental value of each measure among women using the dapivirine vaginal ring (DVR) in the Ring trial in southwestern Uganda.
methodsBetween 2013 and 2016, the International Partnership for Microbicides conducted the Ring trial in which women were randomised to dapivirine or placebo vaginal ring in a ratio of 2:1. A total of 197 women were randomised. Four adherence measures were used, including PK: (i) testing of the dapivirine residual levels in used rings and (ii) plasma drug concentrations; non-PK: (iii) self-reported and (iv) ring colour change, all measured every 4 weeks for 2 years. We defined product use adherence as having the expected dapivirine residual levels (≤ 23.5 mg of 25 mg) or plasma concentration (≥ 95 pg/mL) or having used the ring as instructed at ≥ 80% of the visits completed. We used dapivirine residual levels as a gold standard and measured agreement and incremental value of other measures in predicting residual adherence using Cohen's kappa statistic, a discriminant C-statistic and Receiver Operating Characteristic (ROC) curve, stratified by age < 25 or ≥ 25 years.
resultsOf the 197 women randomised, 66% were aged ≥ 25 years and in both age groups, > 80% completed 2 years of follow-up. In women aged < 25 years, percent agreement between non-PK measures and that between non-PK and PK measures was moderate 57.8% to 66.7%. While that between PK measures was high 86.7%. In the women aged ≥ 25 years, agreements between combinations of measures were 80.5% to 86.2%. The incremental value of non-PK measures was poor in women aged < 25 years, AROC = 0.62, and good in those age 25 + years, area under receiver operating curve (AROC) = 0.77.
conclusionCombining non-PK measures to measure dapivirine residual level adherence in women aged ≥ 25 years could be useful in DVR use, in the context of resource-scarce settings. However, this is of limited value in young women aged < 25 years.
trial registrationReg No. NCT01539226. Registered on February 24, 2012.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.